PDCD1 and non-small cell lung carcinoma: When PD-1/PD-L1 inhibitors were compared with chemotherapy, the risk of dysgeusia of all grades was obviously lower [OR=0.26, 95%CI:(0.19, 0.35), I2 = 0%, Z = 8.44 (P < 0.00001); Figure 5A] (25, 32–35, 37, 41, 43), especially for subgroups relating to NSCLC and UC (32–35, 37, 41, 43).